Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.

[1]  C. Hsieh,et al.  Prevalence of haematuria positively associated with urine albumin excretion in Type 2 diabetes , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[2]  W. Ageno,et al.  Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists , 2012, Thrombosis and Haemostasis.

[3]  G. Sobue,et al.  Microalbuminuria is independently associated with deep or infratentorial brain microbleeds in hypertensive adults. , 2012, American journal of hypertension.

[4]  C. Madden,et al.  Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. , 2012, Journal of neurosurgery.

[5]  J. de Lemos,et al.  Emergency hospitalizations for adverse drug events. , 2012, The New England journal of medicine.

[6]  B. Erstad,et al.  Dosing of 3-Factor Prothrombin Complex Concentrate for International Normalized Ratio Reversal , 2012, The Annals of pharmacotherapy.

[7]  J. Steurer.  [A new risk scheme to predict warfarin-associated hemorrhage risk in anticoagulation with warfarin]. , 2011, Praxis.

[8]  C. Richards,et al.  Emergency hospitalizations for adverse drug events in older Americans. , 2011, The New England journal of medicine.

[9]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[10]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[11]  W. Ageno,et al.  Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists , 2011, Thrombosis and Haemostasis.

[12]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[13]  Gregory Y H Lip,et al.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.

[14]  B. Gersh,et al.  Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. , 2010, American heart journal.

[15]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[16]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[17]  N. Mackman.  The Role of Tissue Factor and Factor VIIa in Hemostasis , 2009, Anesthesia and analgesia.

[18]  K. Hovingh,et al.  Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials , 2008, Thrombosis and Haemostasis.

[19]  Jonathan D Mahnken,et al.  Development of a contemporary bleeding risk model for elderly warfarin recipients. , 2006, Chest.

[20]  J. Hallas,et al.  Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study , 2006, BMJ : British Medical Journal.

[21]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[22]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[23]  J. Dimarco,et al.  Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. , 2005, American heart journal.

[24]  Yuchiao Chang,et al.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003, JAMA.

[25]  J. Olsen,et al.  Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. , 2002, British journal of clinical pharmacology.

[26]  R. Beyth,et al.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.

[27]  E. Hylek,et al.  Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.

[28]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[29]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.